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Effect of Conjugated Bile Salt Taurodeoxycholic Acid 
(TDCA) on Mice Colonic Motor Activity
abstract
Background & Aims: There is an ongoing discussion concerning the 
role of bile salts on the gastrointestinal motility. Therefore, Taurodeoxy-
cholic acid (TDCA) was studied to investigate the effect of TDCA on mice 
colonic motility and to examine this mechanism of action in presences his-
tamine antagonist (pyrilamine maleate salt, H1) and serotonin agonist 
(5-hydroxytryptamine hydrochloride, 5-HT).
Methods: Dose response curve of TDCA was performed using different 
doses of TDCA (0.3, 30, 50, 100, 200, 300 and 500 µM). Peristaltic 
motor complexes (PMCs) amplitudes and intervals of contractions were 
recorded. TDCA inhibitory effect (300 µM) on PMCs was studied with 
presence with H1 (10 µM) and 5-HT (25 µM).
Results: TDCA inhibits intestine motility through increasing PMC 
intervals and decreasing PMC amplitudes with doses of 100, 200, 300 and 
500 µM compared to the control values (P< 0.03, 0.03, 0.01, 0.01 respec-
tively). H1 antagonist (10 µM) induced significant reducing in the PMC 
intervals (137.2 ± 13 S) compared to the control values (255.8 ± 31 S, P < 
0.04) while there was no response of 5-HT agonist (25 µM) on interval or 
amplitude of PMCs regardless applying of TDCA (300 µM).
Conclusion: TDCA directly inhibited colon motility may be due to 
slowing intestinal transit time. These finding is not revealed with presences 
of histamine antagonist and serotonin agonist.
 
IntroductIon
Bile salts are surface active compounds; they have physiological func-tions correlated to their amphipathic molecular structures as diges-
tion and absorption of lipophilic compounds and their detergent nature 
on protein denaturation (1). Bile salts are also considered as effective 
signaling molecules in liver and intestine (2).
Bile salts can be synthesized from cholesterol or extracted from the 
bloodstream by the liver (3). In the liver, bile salts directly modulate their 
hepatocellular uptake, synthesis and biliary secretion via activation of 
nuclear receptors and via modulation of cytosolic signaling cascades. 
They pass from the liver into the small intestine where they reabsorbed 
from the intestinal lumen to undergo enterohepatic circulation (2).
Bile salts are composed of the salts of bile acids combined with taurine 
or glycine during many conversions include deconjugation, oxidation 
and epimerization of hydroxyl groups at C3, C7 and C12, 7-dehydroxyl-
ation, esterification and desulfatation (4). Taurodeoxycholic acid 
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(TDCA) is one of bile salts formed by conjugation of 
deoxycholate with taurine (5).
TDCA inhibits motility, delays gastric emptying and 
inhibits small bowel transit time (6). This inhibition may 
due to molecular mechanisms induce gene expression (7) 
or prostaglandin dependent due to bile acid action on 
intestinal epithelial cells by elicitation chloride ion secre-
tion (8). Kalia et al. (9) supported the bile-induced secre-
tion resulting from increasing concentrations in the colon.
Gastrointestinal (GI) motility could be influenced by 
muscarinic and histaminergic modulation (10). Bile acids 
induce prostaglandin and histamine secretion (8). Hista-
mine is an important cellular messenger of the GI tract 
while histamine antagonist (pyrilamine maleate salt, H1) 
can stimulate various smooth muscles through activation 
of H1 receptors (10).
The secretory actions of TDCA may be partly medi-
ated via a neural pathway through interactions between 
the intestinal nervous and immune systems (9). Serotonin 
(5-hydroxytryptamine; 5-HT) has become one of the 
most investigated and complex biogenic amines (11). Se-
rotonin is found in the enteric nervous system where it is 
implicated in controlling gastrointestinal motor function 
(12) through the receptors of serotonin that mediate reflex 
control of GI motility and secretion (13).
The aim of this study is to investigate the effect of 
TDCA as a bile salt on mice colonic motility and to ex-
amine this mechanism of action in presences of histamine 
antagonist and serotonin agonist.
materIals and methods
experimental animals
Experiments were performed on colon segments from 
Swiss male mice (25– 30 g, 4-wk-old). Animals were kept 
and fed ad libitumin in Animal House of King Fahd 
Medical Research Centre (KFMRC), Jeddah, Saudi Ara-
bia. The study was approved by the Ethics Committee of 
KFMRC, King Abdulaziz University.
chemicals
Sodium taurodeoxycholate hydrate (Taurodeoxycholic 
acid, TDCA) and Pyrilamine maleate salt (Histamine 
antagonist, H1) were purchased from Sigma-Aldrich Cor-
poration (St. Louis, MO USA). 5-Hydroxytryptamine 
Hydrochloride (Serotonin agonist, 5-HT) was purchased 
from Spectrum Chemical Manufacturing Corporation 
(New Brunswick, Gardena, CA).
TDCA was dissolved in dimethylsulphoxide (DMSO, 
0.1%), while H1 antagonist and 5-HT agonist were dis-
solved in distilled water; Solutions were stored at -20°C 
and then they were freshly diluted and added in microli-
ter volumes to the segment bath during the experiments.
tissue preparation
The experiment was performed according to Abdu et 
al. (14, 15); mice were sacrificed by cervical dislocation, 
colon segment was rapidly excised and placed in gassed 
(95% O2 and 5% CO2) Krebs bicarbonate buffer solution 
(composition in mM: 117 NaC1, 4.7 KC1, 25 NaHCO3, 
2.5 CaCl2, 1.2 MgCl2, 2 NaH2PO4, 1.2 H2O, and 11 
D-glucose), cleared of mesenteric connective tissue, and 
the lumen was flushed with Krebs solution. Colon seg-
ment was prepared and mounted horizontally in separate 
20-ml perfusion chambers. The oral and aboral ends of 
colon segment were secured to two metal catheters fixed 
at either end of the chamber; the oral end was connected 
to a perfusion pump for intra-infusion of Krebs solution 
at a rate of 0.16 ml/min, and the aboral end was attached 
to a pressure transducer (NeuroLog™ System, NL900D, 
Digitimer Ltd., Hertfordshire, UK) to record contractile 
activity as changes in intraluminal pressure under iso-
volumetric conditions. Tissues were maintained at 37°C, 
perfused with Krebs solution and allowed to equilibrate 
for at least 10 min before starting of the experiments. The 
productivity from the pressure transducers was transmit-
ted to a data-acquisition system (Power1401, Cambridge 
Electronic Design Ltd., Cambridge, UK) and from there 
to a computer running Spike 2 version 4 software (Cam-
bridge Electronic Design Ltd., Cambridge, UK), which 
stored the records for subsequent offline analysis.
colon motility
Peristaltic motor complexes (PMCs) were measured in 
conditions of their peak amplitude above baseline and 
were expressed as cm/H2O, while period and interval be-
tween them were expressed in seconds (S). PMC ampli-
tudes and intervals of contractions were determined 15 
min before and after appropriate vehicle.
Dose response curve (DRC) was done for TDCA for 
the following doses (0.3, 30, 50, 100, 200, 300 and 500 
μM, n = 28, 4 mice for each dose). H1 antagonist and 
5-HT agonist were added for 5 min after stopping perfu-
sion and prior to challenge with TDCA (300 μM, n = 8, 
4 mice for each chemical), the recording continued for a 
further 15 min.
TDCA dose (300 μM) was selected according to stud-
ied DRC. Dose of H1 antagonist (10 μM) was chosen 
according to Abdu et al. study done in (15) while 5-HT 
agonist (25 μM) dose was obtained according to Michel 
and Kendall study (16).
statistical analysis
Responses are expressed as absolute values ± SE. Data 
compared using „student’s“ t-test paired or unequal vari-
ances as appropriate. Probability of P< 0.05 was consid-
ered as significant.
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results
dose response curve of tdca
The contractile activity of luminal distension of iso-
lated colon segment expressed physiologically by con-
tinuous peaks (amplitudes) separated by relaxation (in-
tervals). The dose response effect of TDCA, a bile salt, 
on the colonic PMCs was done using different doses (0.3, 
30, 50, 100, 200, 300 and 500 μM, n = 28, 4 mice for 
each dose).
TDCA significantly amplified the values of the PMC 
intervals (Fig. 1) in a dose response manner after treat-
ment of the colon with the 100, 200, 300 and 500 μM 
doses compared to the control values (P< 0.03, 0.03, 
0.01, 0.01 respectively).
In the meantime, treatment of the mice colon seg-
ments with TDCA doses caused significant dose re-
sponse drop in the amplitudes of the PMCs at the 100, 
200,300 and 500 μM doses in comparison with the un-
treated colon segments (P< 0.02, 0.03, 0.01, 0.05 respec-
tively, Fig. 2).
effect of tdca in the presence of 
histamine antagonists on pmcs
There was no effect for TDCA treatment (300 μM) 
after incubation of histamine antagonist (H1, 10 μM) on 
interval or amplitude of PMCs of mice colon, Fig. 3. 
Moreover, H1 antagonist (10 μM) induced significant 
reducing in the PMC intervals (137.2 ± 13 S) compared 
to the control values (255.8 ± 31 S, P < 0.04), Fig. 5.
effect of tdca in the presence of 
serotonin agonists on pmcs
The response of serotonin (5-HT, 25 μM) as agonist 
for bile salt TDCA on colonic motility is illustrated in 
Fig. 4 and 6. There was no response of 5-HT agonist (25 
μM) on interval or amplitude of PMCs regardless apply-
ing of TDCA (300 μM).
discussion
The study findings indicate that TDCA inhibits intes-
tine motility through increasing PMC intervals and de-
creasing PMC amplitudes. This finding is demonstrated 
Figure 1. Effect of TDCA on PMC intervals
Effect of different doses (0.3, 30, 50, 100, 200, 300 and 500 mM) 
of TDCA on the PMC intervals. Values represents mean ± SE of 
4 colon segments from different animals. (*P < 0.05) Significantly 
different compared to the control group.
Figure 2. Effect of TDCA on PMC amplitudes
Effect of different doses (0.3, 30, 50, 100, 200, 300 and 500 mM) 
of TDCA on the PMC amplitudes. Values represents mean ± SE 
of 4 colon segments from different animals. (*P < 0.05) Signifi-
cantly different compared to the control group.
Figure 3. Effect of TDCA in the presence of histamine antagonist 
on colon motility
Representative recording traces showing the effect of TDCA (300 
µM) in the presence of histamine antagonist (H1, 10 mM) on 
colon motility.
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with previous studies (6, 8) while it is inconsistent with 
(9, 17). Kalia et al. (9) reported that TDCA increases the 
motility through amplification of intestinal secretion, 
activation of mast cells and other inflammatory cells, 
while Poole et al. (17) suggested the inability of TDCA 
to inhibit contractile activity of the isolated ileum due to 
the hydrophilic property of TDCA which does not ef-
fectively access target neurons within the small intestine.
The ability of TDCA to inhibit motility can be ex-
plained by Mühlbauer et al. (7) who suggested molecular 
mechanisms underlying the bile acid-induced gene ex-
pression; TDCA induced IL-8 expression in a dose and 
time-dependent manner. Martínez-Augustin and his col-
league (8) proposed that TDCA can exert direct actions 
on intestinal epithelial cells by a Ca2+ dependent mecha-
nism which is related by to the actions of bile acids in the 
colon which is claimed to be prostaglandin dependent. 
TDCA can stimulate induction of cyclooxygenase-2 and 
release of prostaglandins (18), moreover, mast cells also 
involve in response to prostaglandins (8).
It is worth to mention that high level of dietary-fat 
intake increases the flow of bile into the intestine, TDCA 
was significantly increased in the high fat-intake (19). This 
is in agreement with this study that TDCA, which is 
synthesized from cholesterol, produced an inhibition of 
intestinal motility.
Figure 4. Effect of TDCA in the presence of serotonin agonist 
on colon motility
Representative recording traces showing the effect of TDCA 
(300 µM) in the presence of serotonin agonist (5-HT, 25 mM) 
on colon motility
Figure 5. Effect of TDCA in the presence of histamine antagonist on interval (A) and amplitude (B) of PMCs
Effect of TDCA (300 µM) in the presence of H1 antagonist (10 mM) on PMCs intervals (A) and amplitudes (B)of mice colon. Values represents 
mean ± SE of 4 colon segments from different animals. *Significantly different compared to the control group, (*P < 0.05).
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Psychological stress plays a major role in functional 
gastrointestinal disorders, it induced activation or sensi-
tization of mucosal mast cells in the GI tract seem to be 
involved in stress-associated alterations of visceral sensi-
tivity (20). Psychological stress accelerated reverse choles-
terol transport (RCT) by compromising intestinal cho-
lesterol absorption (21) confirming the increase in 
releasing of TDCA to inhibit the intestinal motility.
Results from this study confirmed that histamine an-
tagonist (10 μM) induced significant reducing in the 
PMC intervals compared to the control. Earlier studies 
suggested that antagonists mediate by inhibition of cho-
linergic neurotransmission through a pertussis toxin sen-
sitive mechanism (6); Histamine antagonist, can block 
the uptake of monoamines in the central nervous system 
(22), block central muscarinic receptors (23) and block 
H1 receptors-mediated channels (10). On other side, py-
rilamine enhances dopaminergic activity through H1 
receptor blockade at the level of dopamine (22). Cholino-
mimetic mechanisms are also involved in the regulation 
of excitatory action of GI smooth muscles (10).
Although autonomic modulation of GI function oc-
curs via the actions of neurotransmitters and neuromod-
ulators such as serotonin (24) through mediating the re-
ceptors of serotonin of motility and secretion, our results 
showed no response of serotonin agonist (25 μM) on mo-
tor activity with or without TDCA applying (300 μM) 
which is disagreed with previous study (12, 13, 25). This 
discrepancy is explained by small dose of applied sero-
tonin (25 μM) since Sasaki-Adams and Kelley (26) sug-
gested that chronically increased levels of 5-HT may fa-
cilitate modulatory mechanisms.
In conclusion, this study has shown that TDCA di-
rectly inhibited terminal colon motility. It is possible that 
this effect on colon motor activity exposed by slowing 
intestinal transit time. These finding is not revealed with 
low concentration of histamine antagonist and serotonin 
agonist
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